Australian Journal of Chemistry · 2012 · 15 citations · 9 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyEnzyme InhibitionPhosphoinositide SignalingClass I Phosphatidylinositol 3-KinasesKinase InhibitorsPharmacological ScreeningPhosphoinositide 3-Kinase SignalingPhosphoinositide 3-Kinase-akt ActivationPhosphoinositide 3-Kinase-akt SignalingPi3k InhibitorsPi3k Signaling
The thiazolidinedione, compound 1, has previously shown pan-inhibition of the phosphoinositide 3-kinase (PI3K) class I isoforms. We hypothesized the derivatization of the thiazolidinedione core of compound 1 could introduce isoform selectivity. We report the synthesis, characterization, and inhibitory activity of a novel series of 4-iminothiazolidin-2-ones for inhibition of the class I PI3K isoforms. Their synthesis was successfully achieved by multiple pathways described in this paper. Initial in vitro data of 28 analogues demonstrated poor inhibition of all class I PI3K isoforms. However, we identified an alternate target, the phosphodiesterases, and present preliminary screening results showing improved inhibitory activity.
9
Rhodanine derivatives as novel inhibitors of PDE4
Mark W. Irvine, Graham L. Patrick, Justin Kewney et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 54 citations · Full text
Novel GSK-3β inhibitors from sequential virtual screening
Hye Jung Kim, Hyunah Choo, Yong Seo Cho et al. · Bioorganic & Medicinal Chemistry · 2007 · 48 citations · Full text